10-K · March 5, 2026
REGENXBIO Inc. faced a challenging year ending December 31, 2025, with substantial financial losses and regulatory hurdles impacting key programs. Despite notable revenues from license agreements, the company reported a…
Earnings analysis · 10-Q
RGNX earnings analysis
Filed May 14, 2026 · Our reading of the company's report
The latest report
REGENXBIO's Q1 2026 results showed a significant decline in revenues, falling to $6.4 million compared to $89 million in the same quarter the previous year, largely due to a substantial decrease in license and royalty…
Read full summary
REGENXBIO's Q1 2026 results showed a significant decline in revenues, falling to $6.4 million compared to $89 million in the same quarter the previous year, largely due to a substantial decrease in license and royalty revenues. The company reported a net loss of $90.1 million for the quarter, significantly worsening from the net income of $6.1 million a year earlier, alongside cash flow challenges as operating activities consumed $76.2 million, up from positive cash flow in the prior year.
Gross and operating margin
How much of each revenue dollar the business keeps.
One point per quarterly or annual filing. Both margins are shares of that report's revenue.
How we read each report
Our analysis across the last few reports.
Our model's reading of each filing, not the share price or the market's reaction. Annual and quarterly reports each occupy one position.
Reported figures
- Earnings per share
- $-1.72
What stood out
-
Dramatic Revenue Decline
Q1 revenues plunged to $6.4 million, down from $89 million year-over-year.
-
Increased EPS Loss
Reported EPS loss of -$1.72 compared to a gain of $0.12 in Q1 2025.
-
Research & Development Investment Continues
R&D expenses rose to $57.3 million from $53.1 million in Q1 2025.
-
Cash and Cash Equivalents at $150.5M
As of March 31, 2026, the company held $150.5 million in cash and cash equivalents.
-
Operational Cash Flow Loss
Net cash used in operating activities was $76.2 million, a stark contrast to a positive cash flow of $33.6 million in Q1 2025.
-
Significant Increase in Operating Expenses
Total operating expenses rose to $89.8 million, compared to $76.9 million in Q1 2025.
What to watch
-
Sharp Revenue Decline
License and royalty revenue fell by $82 million, significantly impacting financial stability.
-
High Net Loss
Net loss of $90.1 million compared to a net income of $6.1 million in Q1 2025.
-
Cash Burn Rate Increase
Operating expenses increased to $89.8 million, raising concern over cash runway.
Management's outlook
Liquidity outlook indicates current cash, cash equivalents, and securities will sustain operations into early 2027.
Earlier filings 4
10-Q · November 6, 2025
REGENXBIO Inc. reported significant revenue growth in Q3 2025, achieving $29.73 million, a 23.7% increase from the prior quarter's $24.19 million and up 11.1% year-over-year. Although the company continues to face…
10-Q · August 7, 2025
REGENXBIO reported disappointing Q2 2025 results with a revenue of $21 million, down 6% from the previous quarter and significantly below estimates. The net loss increased to $70.9 million as operating expenses grew,…
10-Q · May 12, 2025
RGNX reported strong revenue growth in Q1 2025, with total revenues increasing to $89M driven by significant licensing revenue from new collaborations. However, the company posted lower-than-expected diluted EPS of…
This is our reading of a public filing, not the filing itself. Analysis can contain errors; check the source document for full context.